Trading Profile: CorMedix, Inc., a development-stage biopharmaceutical company, develops, manufactures, and markets products that lock a patient's central venous catheter between hemodialysis sessions to keep it free of infection and clots. It provides CMX001 that reduces oxidative stress due to excess labile iron; CMX002, a diagnostic test for chronic kidney disease; CMX003, an antimicrobial/anticoagulant solution; and CMX004, a pressure-sensitive gel. The company was incorporated in 2006 and is based in Bridgewater, New Jersey.
»»» Detailed Company Profile & Chart
CorMedix Inc current day financials: 2024-04-26 12:48:06am| Symbol | Name | Purchase price | Last Price | Change | % Change |
|---|---|---|---|---|---|
| 0.00 | |||||
Recent CRMD News from Yahoo Finance & Seeking Alpha
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath »
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the Center for Medicare & Medicaid Services (CMS) has determined that DefenCath® meets the criteria for a Transitional Drug Add-On Payment (TDAPA) in the anti-infective functional category, beginning on July 1, 2024. The TDAPA program currently provides
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin) »
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced DefenCath® (taurolidine and heparin) catheter lock solution (CLS) is now commercially available for U.S. inpatient use. DefenCath (taurolidine and heparin) is approved by the U.S. Food and Drug Administration (FDA) to reduce the incidence of catheter-related
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference »
BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that two abstracts have been accepted for presentation at the Society for Healthcare Epidemiology of America (SHEA) conference being held in Houston, Texas, April 16 – 19, 2024. The first abstract being presented examines in vitro antimicrobial activity of taurolidine against a
CorMedix enters into 5-year agreement with ARC Dialysis »
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC »
BERKELEY HEIGHTS, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath® (taurolidine and heparin). CorMedix received NDA approval of DefenCath® under the Limited Population Pathway for Antibacterial and A
Older Archived News CorMedix Inc
- CorMedix (CRMD) Stock Gains After Receiving Positive FDA Feedback for Neutrolin.
- Cormedix (CRMD): Today's Weak On High Volume Stock.
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CorMedix, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of September 4, 2015.
- SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in CorMedix, Inc. To Contact the Firm Ahead of Imminent Lead Plaintiff Deadline.
- Pacific Premier Bancorp, Inc. Announces the Appointment of New Director.
- NEUTROLIN LABEL EXPANSION APPROVED IN GERMANY.
- Law Offices of Howard G. Smith Reminds Investors: Two Days Left To File Lead Plaintiff Motion In The Class Action Lawsuit Against CorMedix, Inc..
- How Is Smart Money Trading CorMedix Inc..
- FINAL NOTICE OF DEADLINE: Khang & Khang LLP Reminds Investors with Losses in CorMedix, Inc. of the September 4, 2015 Deadline.
- CorMedix, Inc. to Announce Third Quarter 2015 Results on November 12, 2015.Load More News...
